What this study is
The purpose of this study is to better understand how people's mood, behavior, and brains respond to different recreational drugs. We are also trying to understand why some people may feel differently or their brain may respond differently than other people after taking the same recreational drug.
What's being tested
- Placebo Oral Capsule
Intervention · DRUG
A capsule that contains only dextrose filler administered during the first or second laboratory visit.
- THC
Intervention · DRUG
A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
Study details
- Sponsor
- University of Illinois at Chicago
- Conditions
- Cannabis Use · Substance Use Disorder (SUD) · Healthy
- Enrolling
- 144 people
- Starts
- 2027-01-04
- Est. completion
- 2031-06
- Design
- Triple-blind, randomized, crossover, Early Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 21 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Age 18-21 at eligibility visit
- Body mass index of 18.5-30
- Report using cannabis ≥10 times in their life and ≥1 time in the past 3 months, but <7 days a week (daily)
- Medically and neurologically healthy
- Score of ≥0.25 on the Personality Inventory for DSM-5 (PID-5) Anhedonia subscale
You can't join if
- Positive urine drug screen (UDS; except for THC) and/or positive saliva THC test
- Contraindication for fMRI BOLD study (e.g., metal implants)
- Severe mental illness (e.g., psychosis, mania, lifetime moderate-to-severe SUD (including moderate-to-severe CUD))
- Heavy nicotine use in the past month (>20 cigarettes per week or electronic nicotine delivery system (ENDS) use equivalent
- Night shift work
- Females who are currently pregnant confirmed by urine pregnancy test, are planning pregnancy, or are lactating
- Unwilling/unable to sign informed consent document
- Current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substances (Dronabinol/Marijuana/Cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide)
- Physical or neurological diagnoses (e.g., cancer, diabetes, seizure disorder, Parkinson's, Multiple Sclerosis, loss of consciousness >10 min., etc.) that in the opinion of the Study Physician and Investigators could increase safety risks or influence the findings
- Currently taking any medication that could interact with a single dose of Δ9-THC
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Illinois at Chicago
Chicago, Illinois, United States
- Natania Crane, PhD · Contact(312) 413-4453ncrane3@uic.edu
Study team
Sponsor
University of Illinois at Chicago
Study ID STUDY2024-0596
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.